Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTQ923 genome-edited HSPCs in sickle cell disease
NCT04443907Phase 1Terminated
- Sponsor
- Novartis
- Start
- Aug 2020
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Adoptive Cell Transfer, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of OTQ923 in sickle cell disease (SCD) (2 arms), sponsored by Novartis. Primary endpoints: Adverse Events at 24 months, Serious Adverse Events at 24 months and 2 more. Started Aug 2020; status: terminated.
02
Drugs
OTQ923
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04443907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443907.